Ivesa Application Scope

Ivesa is an oral, selective third-generation EGFR tyrosine kinase inhibitor (brand name for furmonertinib), used to treat EGFR-mutated non‑small cell lung cancer.

ivesa

Characteristics

Ingredients: Furmonertinib Mesylate

Properties:
- Selectively inhibits mutant EGFR (T790M, L858R, exon 19 deletions)
- Irreversible binding with good brain penetration; less activity on wild-type EGFR
Packaging Specification: Film-coated tablets, typically 80 mg or 160 mg strength

Storage: Store at room temperature in a dry environment, per label
Expiry Date: As indicated on the specific packaging label
Executive Standard: Manufactured to China NMPA standards; falls under ATC code L01XE
Approval Number: China NMPA conditional approval on March 3, 2021, for T790 M-positive NSCLC
Date of Revision: Label updates aligned with FURLONG trial data (published March 2022)
Manufacturer: Shanghai Allist Pharmaceuticals Co., Ltd.

Guidelines for the Use of Ivesa

Dosage and Administration:
- Standard dose: 80 mg orally once daily, until disease progression or unacceptable toxicity
- Higher dosing (160–240 mg QD) was explored in ex20ins-mutant NSCLC with promising PFS
Adverse Reactions:
- Common: elevated AST/ALT, rash, decreased WBC count, proteinuria, QT prolongation
Contraindications: Known hypersensitivity to furmonertinib or excipients
Precautions:
- Monitor liver enzymes and ECG periodically
- Use caution in patients with moderate–to–severe hepatic or renal impairment

Ivesa Interactions

Drug Interactions:
- Substrate of CYP3A4/CYP3A5; avoid strong inhibitors or inducers
- May affect transporters like P-gp or BCRP; possible interactions with hormonal contraceptives

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.